Lupus & antiphospholipid syndrome
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics
Authors' conclusion
We implemented a lupus PtDA with varied success rates during the COVID pandemic; more providers were associated with higher clinic penetration. Clinical personnel perceived high lupus PtDA appropriateness, acceptability, feasibility, success, and permanence that persisted up to 24 months.
Study context
- Population
- Patients with SLE and clinical personnel in 15 geographically diverse US rheumatology outpatient clinics, 2019–2024 (including the COVID pandemic)clinical personnel
- Participants
- 184 patients
- Outcome
- Percent penetration/reach: number of patients who viewed the lupus PtDA at end of study divided by total eligible patients (times 100)
- Follow-up
- End of the study
Methodological detailsmulticentre, 15 rheumatology outpatient clinics
- Multicentre
- 15 rheumatology outpatient clinics
Main finding
As reported in the abstract
Penetration (primary outcome) across 15 clinics
Penetration range across clinics
3% to 44%
Further findings
Baseline ORIC scores (0-5, higher = better), range across sites
- Commitment
- 3.5 to 4.2
- Efficacy
- 3.4 to 4.4
Baseline TLPSS scores (0-7, higher = better), range across sites
- Internal learning
- 3.9-5.5
- External learning
- 3.7-5.6
- Psychological safety
- 4.3-5.5
Clinical personnel-perceived lupus patient decision-aid (PtDA) outcomes (scales 1-5, higher = better), optimal at 4 months
- Appropriateness, mean (SD 0.86)
- 3.43
- Acceptability, mean (SD 0.83)
- 3.53
- Feasibility, mean (SD 0.71)
- 3.44
- Success, mean (SD 0.73)
- 3.41
- Permanence, mean (SD 0.74)
- 3.22
Original publication
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics. Rheumatology (Oxford). Published 12 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →